Logo

Sunovion Pharmaceutical's Kynmobi (apomorphine hydrochloride) Receives the US FDA's Approval to Treat Parkinson's Disease Off Episodes

Share this

Sunovion Pharmaceutical's Kynmobi (apomorphine hydrochloride) Receives the US FDA's Approval to Treat Parkinson's Disease Off Episodes

Shots:

  • The approval is based on P-III study which involved assessing of kynmobi vs PBO in patients with Parkinson’s Disease Off Episodes
  • The study resulted in improvements in motor symptoms at 30 minutes after dosing @12 wks.- mean reduction of 7.6 points- initial clinical improvements were seen at 15 minutes post-administration full ON response within 30 minutes @12wks.- well-tolerated
  • Kynmobi sublingual film used to treat short-term (acute)- intermittent “off” episodes in people with Parkinson’s disease with expected availability in Sep 2020

Click here to read full press release/ article | Ref: Sunovion Pharmaceuticals | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions